🇺🇸

US SEC Filing Intelligence

· daily

US Corporate Distress Financial Stress SEC Filings — June 24, 2026

The 50 filings reveal a bifurcated corporate landscape on June 24, 2026, with acute distress signals concentrated in micro-cap and pre-revenue biotech/tech companies, while larger, established firms engage in routine capital management. The most critical developments include the imminent delisting of Aditxt (ADTX) and the high-risk reverse split at SRx Health Solutions (SRXH), both representing terminal distress. A significant theme is the aggressive use of reverse stock splits and dilutive financing by cash-strapped companies to maintain exchange listings, a pattern that has historically failed. Conversely, several companies are executing strategic pivots: Comstock Inc. sold legacy mining assets for $45M+ to focus on renewable metals, and Hyperscale Data secured a $1.2B+ AI compute contract, signaling a shift from crypto to AI infrastructure. The data also shows a wave of SPAC activity (Churchill Capital XI, Gores Holdings XI, Wilco 63) targeting AI and robotics, indicating strong market appetite for exposure to these themes. Period-over-period data, where available, shows revenue growth at Worksport (+47.9% YoY) and margin improvement, but this is overshadowed by the company's cash flow negativity. The overarching theme is a 'survival of the fittest' dynamic where companies with clear strategic direction and access to capital are thriving, while those with weak fundamentals and repeated compliance failures are facing extinction.

50 high priority 50 total filings
· daily

US Corporate Board Director Changes SEC Filings — June 24, 2026

This digest of 21 SEC filings reveals a significant wave of C-suite departures and board-level transitions across the US market on June 24, 2026. The most critical development is a cluster of CFO resignations at Grove Collaborative, Vicarious Surgical, and the departure of Elastic's CPO, signaling potential strategic shifts or financial stress at these growth-stage companies. A notable pattern is the rise of 'strategic reorganizations' at HeartBeam, BellRing Brands, and Elastic, which are simultaneously announcing leadership changes alongside workforce reductions or business model pivots, creating a mixed sentiment. Insider activity is sparse in these filings, but the high volume of director elections at annual meetings (CarMax, Brookdale, CAVA) shows strong shareholder support for incumbent boards, with only minor dissent at GitLab and CAVA. The period-over-period data is limited as most filings are event-driven 8-Ks, but forward-looking statements from BellRing Brands ($10-12M in annualized savings) and Elastic ($22-25M in restructuring charges) provide quantifiable targets for investors to monitor. Overall, the theme is one of corporate recalibration, with companies streamlining leadership and operations, which presents both risks (execution uncertainty) and opportunities (cost savings, strategic focus).

21 high priority 21 total filings
· daily

USA Insider Trading Pulse — June 24, 2026

Today's insider trading pulse reveals a market characterized by significant insider selling at high-growth and technology companies, contrasting with selective insider buying in value-oriented and distressed sectors. Notable large-scale disposals by a 10% owner at Workday ($5.6M), a director at Dell Technologies ($5M), and the President of R&D at Relay Therapeutics ($1.6M) signal potential overvaluation or strategic de-risking at current levels. Conversely, a substantial $8M preferred stock acquisition by a 10% owner at Presurance Holdings and a $1.34M open-market purchase by the Executive Chairman of American Shared Hospital Services indicate strong insider conviction in these specific stories. The data also highlights a wave of director stock awards at CAVA Group, suggesting a focus on long-term alignment. A cluster of insider selling in the biotech sector, particularly at Relay Therapeutics and NewAmsterdam Pharma, warrants caution. Overall, the pattern suggests insiders are taking profits in high-multiple names while deploying capital into perceived undervalued or special situation equities.

49 high priority 1 medium 50 total filings
· daily

US Merger & Acquisition SEC Filings — June 24, 2026

The US M&A landscape on June 24, 2026, is characterized by a strong bifurcation between successful, high-confidence deal closures and struggling blank-check companies facing shareholder dissent. The period's most significant event is the completion of **Centessa Pharmaceuticals'** acquisition by Eli Lilly for $38.00 per share plus CVRs, a high-materiality event that removes a public company from the market. In the SPAC space, **Alpha Star Acquisition Corp** achieved overwhelming shareholder approval for its business combination with XDATA Group, with a negligible 46 shares redeemed, signaling strong market confidence. Conversely, **Quartzsea Acquisition Corp** faced significant shareholder pushback, with 11.2% of shares redeemed to approve a simple extension, highlighting a trust deficit. The IPO of **Texas Ventures Acquisition IV Corp** adds a new $150 million vehicle to the market, while **Spring Valley Acquisition Corp. III** secured a small working capital loan to sustain operations. The aggregate data shows a clear trend: SPACs with credible targets and strong execution (Alpha Star) are rewarded, while those without a clear path (Quartzsea) face redemptions and uncertainty.

5 high priority 5 total filings
· monthly

US Pre-Market SEC Filings Roundup — June 24, 2026

Overnight filings reveal a dynamic landscape with significant capital markets activity, insider transactions, and strategic corporate actions. Key themes include a wave of IPOs and offerings (Ambiq Micro, SK hynix, Capstone 72, Liminatus Pharma), major insider selling at Spyre Therapeutics, and a transformative asset sale by Comstock Inc. Period-over-period comparisons are limited in these filings, but forward-looking data points to upcoming catalysts, such as the closing of Green Dot's merger and EagleRock Land's first earnings call. Insider activity is mixed, with stock awards at CXApp and Domo contrasting with significant sales at Spyre and Aura Minerals. The most critical developments include the overwhelming shareholder approval for Green Dot's merger, the massive block trade by Fairmount Funds in Spyre, and the strategic pivot by Comstock. These events signal potential volatility and opportunities in fintech, biotech, and materials sectors.

35 high priority 15 medium 50 total filings
· daily

Biotech Small-Cap Approvals — June 23, 2026

During the period of June 23, 2026, the FDA issued 9 approvals, all classified as 'Other' (non-NME, non-biosimilar, non-label-expansion per the provided data), with 8 neutral signals and 1 bullish signal. The dominant theme is a wave of generic/biosimilar approvals for established small molecules, including multiple entrants for SOLRIAMFETOL HYDROCHLORIDE (HIKMA and ALKEM LABS LTD) and a cluster of approvals for hematology/oncology agents like ELTROMBOPAG OLAMINE (ACTAVIS LABS FL) and FOSTAMATINIB DISODIUM (ANNORA PHARMA). The highest-conviction signal is the bullish label expansion for APREPITANT by AZURITY, which could extend the drug's utility and revenue stream. Key risk: the lack of NME approvals signals a quiet period for novel drug catalysts, and the generic approvals for BALOXAVIR MARBOXIL (NORWICH) and ATOMOXETINE HYDROCHLORIDE (CREEKWOOD PHARMS) will pressure originator pricing in influenza and ADHD markets, respectively.

9 total filings
· daily

NME Blockbuster Approvals — June 23, 2026

This period's FDA digest covers a single NME approval, TEBIPENEM, PIVOXIL (UTEBZI) from GLAXOSMITHKLINE LLC, which received Priority Review and is classified as a FALLBACK approval type. The approval is assessed as bullish with high confidence, reflecting the unmet need addressed by this new oral antibiotic. No biosimilar or label expansion approvals were recorded, limiting broader sector signals. The highest-conviction signal is the NME approval itself, which strengthens GSK's pipeline credibility in infectious disease. Key risks include the lack of disclosed commercial data (peak sales, pricing, exclusivity) and the FALLBACK designation, which may imply a narrower indication or conditional approval.

1 total filings
· daily

Big Pharma Approvals — June 23, 2026

This single-approval period features GlaxoSmithKline's NME tebipenem pivoxil (UTEBZI), a Priority Review oral carbapenem antibiotic for complicated urinary tract infections. The approval is classified as a 'fallback' type, suggesting it may serve as a second-line or reserved therapy, which tempers the commercial upside relative to a first-line NME launch. Despite the bullish signal (8/10 strength, 8/10 materiality), the lack of disclosed peak sales estimates, exclusivity duration, or pricing power leaves significant uncertainty around revenue potential. The dominant therapeutic area theme is anti-infectives, but with only one approval, no sector-wide clustering is evident. The key risk is the absence of commercial detail and the fallback designation, which could limit market penetration versus existing oral and IV alternatives.

1 total filings
· daily

New Drug Approvals (Original) — June 23, 2026

During the period of June 23, 2026 to June 23, 2026, the FDA issued 10 approvals, all classified as 'Other' (FALLBACK), with zero NMEs, zero biosimilars, and zero label expansions. The dominant theme is a wave of generic/biosimilar-like approvals for established molecules, with two exceptions flagged as bullish: GSK's NME TEBIPENEM PIVOXIL (UTEBZI) received Priority Review, representing a high-conviction signal for a novel oral antibiotic, and AZURITY's label expansion for APREPITANT. The highest-conviction signal is GSK's TEBIPENEM PIVOXIL approval, which, as a new molecular entity with Priority Review, signals a potential commercial opportunity in the anti-infective space. Key risks include the lack of disclosed commercial data for all approvals, making peak sales and pricing power assessments impossible, and the neutral-to-low materiality of the 8 remaining approvals which are largely generic entries.

10 total filings
· daily

DHS Homeland Security Contracts — June 23, 2026

The single contract analyzed, a $138.3 million firm-fixed-price delivery order from the Transportation Security Administration (TSA) to Analogic Corp, signals a long-term, competitive win in the civilian airport security detection market. The contract, which has a potential value of $499.7 million including options through 2033, is fully civilian (0% defense-related) and reflects sustained TSA investment in advanced computed tomography (CT) technology. The highest-conviction signal is the competitive nature of the award—full and open competition with no set-aside—indicating Analogic's technological edge over rivals. A key risk is the firm-fixed-price structure, which places execution and cost-overrun risk on Analogic, and the medium contract risk rating suggests careful monitoring of margin performance is warranted.

1 total filings
· daily

HHS & Healthcare Contracts Intelligence — June 23, 2026

The June 23, 2026 HHS contracts digest totals $262.8 million in obligations, split entirely between two civilian-sector awards from HHS agencies (BARDA and NIH/NCI). The largest contract is a $141.3 million biotechnology R&D award to START2 GROUP, INC., an early-stage small disadvantaged business, raising execution risk given only $2.8 million outlayed to date. Leidos Biomedical Research’s $121.5 million cost-plus-fixed-fee award provides stable, low-risk revenue through August 2024, but with modest profit upside. The dominant sector theme is sustained federal health R&D investment, though both contracts exhibit neutral signals with no clear bullish catalysts, while START2 GROUP’s performance milestone risk is a key watch item for investors tracking small-cap government services exposure.

2 total filings
· daily

New Federal Contractors — June 23, 2026

The three contracts awarded between June 23, 2026, and June 23, 2026, total $401.1 million, with one-third defense-related and an average signal strength of 5.7/10. The dominant theme is civilian health and security spending, led by HHS ($262.8M combined across START2 GROUP and Leidos Biomedical) and DHS/TSA ($138.3M to Analogic Corp). Highest-conviction signal is the bullish, competitive win by Analogic Corp for $138.3M in TSA CT systems, offering long-term revenue visibility through 2033. Key risk is execution and scalability for START2 GROUP, a small, foreign-owned disadvantaged business with only $2.8M outlayed on a $141.3M BARDA contract, presenting high pricing risk and early-stage funding gaps.

3 total filings
· daily

Significant Contract Modifications ($10M+) — June 23, 2026

The three contracts analyzed total $401.1 million in obligations, with a civilian-heavy split (2/3 HHS, 1/3 DHS) and no direct DoD awards. The dominant theme is federal investment in advanced health R&D and airport security technology, with BARDA (HHS) and TSA (DHS) as key agencies. The highest-conviction signal is the bullish $138.3 million TSA CT system award to Analogic Corp, reflecting competitive strength and long-term revenue visibility through 2033. Key risks include the early-stage, high-execution-risk $141.3 million BARDA contract to START2 GROUP, INC., which has only $2.8 million outlayed, and the upcoming August 2024 expiration of Leidos Biomedical Research's $121.5 million NIH contract, which creates re-compete uncertainty.

3 total filings
· daily

Contract Deobligations Alert — June 23, 2026

This digest covers $401.1 million in total obligations across three contracts, with a 2:1 civilian-to-defense split (HHS and DHS vs. no pure DOD awards). The highest-conviction signal is Analogic Corp's $138.3 million TSA CT system delivery order, a competitive win in a growing airport security market with $499.7 million in potential value through 2033. The largest contract, START2 GROUP's $141.3 million BARDA biotechnology R&D award, carries high execution risk due to only $2.8 million outlayed and the company's small, foreign-owned status. A key risk is the upcoming August 2024 expiration of Leidos Biomedical Research's $121.5 million NIH contract, which may signal a re-compete or budget shift for NIAID vaccine research.

3 total filings
· daily

Contract Option Exercises — June 23, 2026

The three contracts totaling $401.1 million are heavily skewed toward civilian agencies (HHS and DHS), with only one-third defense-related, reflecting continued federal investment in health security and advanced airport screening technology. The highest-conviction signal is Analogic Corp's $138.3 million TSA delivery order for CT systems, a competitive win with a potential $499.7 billion ceiling that underscores durable demand for aviation security upgrades. Key risks include execution uncertainty on START2 Group's early-stage $141.3 million BARDA contract (only $2.8 million outlayed) and the pending August 2024 renewal of Leidos' $121.5 million NIH contract. Investors should monitor TSA budget cycles for Analogic's option exercises and START2 Group's milestone progress as critical catalysts.

3 total filings
· daily

All HHS Contracts — June 23, 2026

This digest covers two HHS contracts totaling $262.8 million, both civilian (non-defense) awards, with a dominant theme of federal health R&D spending. The highest-conviction signal is Leidos Biomedical Research’s $121.5 million cost-plus-fixed-fee delivery order from NIH/NCI, which provides stable, predictable margins through August 2024 but caps upside. The more speculative signal is START2 GROUP’s $141.3 million BARDA contract, which carries high execution risk due to only $2.8 million outlayed to date and the company’s small, foreign-owned status. Key risk: START2’s contract is early-stage and milestone-dependent, with potential for delays or protest vulnerability. Key watch item: Leidos’ contract renewal or follow-on award after August 2024, which will signal NIH budget continuity for vaccine research.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — June 23, 2026

The three contracts totaling $401.1 million are overwhelmingly civilian, with two HHS awards and one DHS award; only the TSA contract for Analogic Corp carries a defense-adjacent security mission. The highest-conviction signal is Analogic Corp's $138.3 million delivery order for full-sized CT systems, which provides long-term revenue visibility through 2033 and reflects competitive strength in airport security technology. The largest contract by value, START2 GROUP, INC.'s $141.3 million BARDA award, carries high execution risk due to minimal outlays ($2.8M) and a small, foreign-owned contractor profile. A key risk is the impending expiration of Leidos Biomedical Research's $121.5 million NIH contract in August 2024, which creates a re-compete event that could affect Leidos' health R&D revenue stream.

3 total filings
· daily

High-Value Federal Grants ($5M+) — June 23, 2026

This digest covers $401.1 million in high-value federal obligations from June 23, 2026, with a 1:2 defense-to-civilian split. The dominant theme is advanced technology procurement for health/biodefense (HHS/BARDA and NIH) and homeland security (TSA). The highest-conviction signal is Analogic Corp's $138.3 million TSA CT system delivery order, which provides long-term revenue visibility through 2033 and signals competitive strength in airport security detection. A key risk is the START2 GROUP, INC. $141.3 million BARDA contract, where only $2.8 million has been outlayed, indicating early-stage execution risk and potential scalability concerns for a small, foreign-owned firm.

3 total filings
· daily

General Federal Contracts — June 23, 2026

The three contracts analyzed total $401.1 million in obligations, with a civilian-heavy split (2 of 3 from HHS, 1 from DHS) and no direct defense awards, though the DHS TSA contract supports national security infrastructure. The dominant sector theme is health and biodefense R&D, driven by BARDA and NIH funding, with a secondary theme in advanced airport security technology via TSA. The highest-conviction signal is the bullish $138.3 million Analogic Corp TSA CT systems delivery order, which offers long-term revenue visibility through 2033 and reflects competitive strength in a high-value security niche. A key risk is the $141.3 million START2 GROUP contract with BARDA, where only $2.8 million has been outlayed, signaling early-stage execution risk and potential milestone delays.

3 total filings
· daily

S&P 500 Technology Sector SEC Filings — June 23, 2026

The 22 filings from S&P 500 Technology constituents on June 23, 2026, reveal a sector defined by massive capital returns, significant insider profit-taking, and a governance overhang at Snowflake. Accenture's $7.5B buyback program and IBM's credit facility extension signal robust balance sheet strength and shareholder return commitments. However, a wave of insider selling, particularly the $119M sale by NVIDIA Director Mark Stevens and substantial sales by CrowdStrike's top executives, introduces a cautionary note, suggesting insiders are locking in gains amid elevated valuations. The period-over-period data, while not directly present in these specific filings, is reflected through the scale of capital deployment and insider actions. The key themes are capital allocation confidence versus insider valuation concerns, with Snowflake's proxy fight representing a distinct corporate governance risk. Investors should monitor these patterns for potential divergence between management actions and market sentiment.

20 high priority 2 medium 22 total filings